ClinicalTrials.gg

Program

fosfomycin sodium

Also written as “ZTI-01”, “ZTI-01 100 mg/kg” and “ZTI-01 75 mg/kg”.

Its studies are mostly in Precursor Cell Lymphoblastic Leukemia-Lymphoma · Pyelonephritis, led by 2 companies.

Furthest: phase 4, since Apr 13, 20164 company-led studies, 2 open or runningNext primary completion: Sep 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Nabriva Therapeutics31 open or runningphase 3since Apr 13, 2016Apr 13, 2016none ahead
Meitheal Pharmaceuticals11 open or runningphase 4since May 8, 2026May 8, 2026Sep 2027phase 4 · NCT07618299

Also a collaborator on its studies: medpace-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 13, 2016First study: phase 3 study in Urinary Tract Infection SymptomaticNew to Nabriva TherapeuticsNabriva Therapeutics · NCT02753946 · 465 enrolled · United States, Belarus, Bulgaria and more
  2. May 8, 2018Phase 1 study in Cardiac Repolarization in Healthy SubjectsNabriva Therapeutics · NCT03709927 · 41 enrolled · United States
  3. Oct 10, 2018Phase 1 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNabriva Therapeutics · NCT03709914 · 21 planned · United States
  4. May 8, 2026Meitheal Pharmaceuticals's first study: phase 4 study in Healthy Lactating WomenNew to Meitheal PharmaceuticalsMeitheal Pharmaceuticals · NCT07618299 · 24 planned · South Africa

Ahead

  1. Sep 2027Primary completion: phase 4 study in Healthy Lactating WomenMeitheal Pharmaceuticals · NCT07618299

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor”ChEMBL 37, by rule

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07618299Healthy Lactating Women · South Africa4RecruitingMeitheal PharmaceuticalsSep 202724
NCT03709914Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States1RecruitingNabriva TherapeuticsDec 31, 202521
NCT03709927Cardiac Repolarization in Healthy Subjects · United States1CompletedNabriva TherapeuticsApr 12, 201841
NCT02753946Urinary Tract Infection Symptomatic · United States, Belarus, Bulgaria and more3CompletedNabriva TherapeuticsJan 12, 2017465

How it is read

Names in the registry

  • “ZTI-01”, 3 entries
  • “ZTI-01 100 mg/kg”, 1 entry
  • “ZTI-01 75 mg/kg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.